RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736) WITH OR WITHOUT DOSE TITRATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA To compare the objective response rate (ORR) in patients receiving axitinib with or without dose titration (Arms A and B)

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical trial to determine if the investigational MnB vaccine works when 2 or 3 doses of the vaccine is given to adolescents Co-Primary Objectives: To assess the immune response as measured by serum bactericidal assay performed with MnB strains expressing LP2086 subfamily A and B proteins, measured 1 month after the thi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAILURE OF ONE PRIOR ANTIANGIOGENIC THERAPY Primary Objective:  To compare the OS of patients with advanced HCC receiving axtitinib + best supportive care (BSC) versus (vs) placebo + BSC following failure of one prior antiangiogenic therapy.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 16 WEEK OPEN-LABEL OUTPATIENT, RANDOMIZED, PARALLEL STUDY ASSESSING THE IMPACT OF TWO DIFFERENT INITIAL DOSE PRESCRIPTIONS FOR DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE POORLY CONTROLLED ON A COMBINATION OF TWO OR MORE ORAL AGENTS The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is noninferior compared t...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 17-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER TRIAL OF PREGABALIN FOR THE TREATMENT OF CHRONIC CENTRAL NEUROPATHIC PAIN AFTER SPINAL CORD INJURY To evaluate the efficacy of pregabalin compared with placebo for the treatment of chronic central neuropathic pain after spinal cord injury.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NOVO KIDNEY ALLOGRAFT RECIPIENTS 1) To compare the incidence of clinical biopsy-proven acute rejection (BPAR) (as interpreted by the central blinded pathologist) of combination regimens of CP-90,550 and mycophenolate mofetil (MMF) / ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study in patients with Non-Hodgkin Lymphoma (NHL) to evaluate safety and effectiveness of a new drug combination compared to 2 other drug combinations that have already been studied in clinical trials. This study will include patients who have already received therapy for their NHL (but it returned or was not completely cured), and now intense chemotherapy is not the best treatment option due to reasons like health or age. The types of NHL include Diffuse Large B-Cell Lymphoma and others  To evaluate efficacy as measured by overall survival (OS), with a goal of demonstrating the superiority of inotuzumab ozogamicin when administered in combination with rituximab, compared with an act...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC)  Compare the progression-free survival (PFS) of treatment-naïve patients with mRCC receiving AG-013736 vs sorafenib.  Estimate the progression-free survival (PFS) of previously-treated Asian patien...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 To estimate the incidences of LPD, lymphoma and important infections over 2 years in subjects with RA who completed or discontinued a qualifying CP 690,550 clinical trial (randomized clinical trial wi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE TREATMENT OF SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE ALONE The primary objective is to compare the efficacy of 6 dose levels of oral CP 690,550 (20 mg once daily [QD] and 15 mg, 10 mg, 5 mg, 3 mg and 1 mg twice daily [BID]), versus placebo, for the treatment ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune